Clinical Trial Update: Sorafenib and TRC105 in Hepatocellular Cancer [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion and posted results of a Phase 1/Phase 2 trial evaluating sorafenib in combination with TRC105 for hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• TRC105 (carotuximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hepatoma, Liver Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-01-23